Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska, Elisa A. Rozeman, Robyn P.M. Saw, Winan J. van Houdt, Hanna Eriksson, W. Martin C. Klop, Sydney Ch’ng, Johannes V. van Thienen, Henk Mallo, Maria Gonzalez, A. Torres Acosta, Lindsay G. Grijpink-Ongering, A. van der Wal, Annemarie Bruining, Bart A. van de Wiel, Richard A. Scolyer, John B.A.G. Haanen, Ton N. Schumacher, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank
Topics & Concepts
MedicineIpilimumabNivolumabOncologyInternal medicineNeoadjuvant therapyMelanomaStage (stratigraphy)CancerImmunotherapyCancer researchBreast cancerPaleontologyBiologyCutaneous Melanoma Detection and ManagementMelanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers